High-dose intravenous vitamin C decreases rates of mechanical ventilation and cardiac arrest in severe COVID-19.
Ascorbic acid
Intensive care
SARS-CoV-2
Treatment
Vitamin C
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
30
03
2021
accepted:
22
02
2022
pubmed:
30
3
2022
medline:
14
9
2022
entrez:
29
3
2022
Statut:
ppublish
Résumé
Intravenous vitamin C (IV-VitC) has been suggested as a treatment for severe sepsis and acute respiratory distress syndrome; however, there are limited studies evaluating its use in severe COVID-19. Efficacy and safety of high-dose IV-VitC (HDIVC) in patients with severe COVID-19 were evaluated. This observational cohort was conducted at a single-center, 530 bed, community teaching hospital and took place from March 2020 through July 2020. Inverse probability treatment weighting (IPTW) was utilized to compare outcomes in patients with severe COVID-19 treated with and without HDIVC. Patients were enrolled if they were older than 18 years of age and were hospitalized secondary to severe COVID-19 infection, indicated by an oxygenation index < 300. Primary study outcomes included mortality, mechanical ventilation, intensive care unit (ICU) admission, and cardiac arrest. From a total of 100 patients enrolled, 25 patients were in the HDIVC group and 75 patients in the control group. The average time to death was significantly longer for HDIVC patients (P = 0.0139), with an average of 22.9 days versus 13.7 days for control patients. Patients who received HDIVC also had significantly lower rates of mechanical ventilation (52.93% vs. 73.14%; OR
Identifiants
pubmed: 35349005
doi: 10.1007/s11739-022-02954-6
pii: 10.1007/s11739-022-02954-6
pmc: PMC8961256
doi:
Substances chimiques
Antineoplastic Agents
0
Ascorbic Acid
PQ6CK8PD0R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1759-1768Informations de copyright
© 2022. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).
Références
https://coronavirus.jhu.edu/map.html
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Leutkemeyer A (2020) Remdesivir for the treatment of Covid-19—final report. N Engl J Med 383:1813–1826. https://doi.org/10.1056/NEJMoa2007764
doi: 10.1056/NEJMoa2007764
pubmed: 32445440
Gibson PG, Qin L, Puah SH (2020) COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre- COVID-19 ARDS. Med J Aust 213:54–56. https://doi.org/10.5694/mja2.50674
doi: 10.5694/mja2.50674
pubmed: 32572965
pmcid: 7361309
Carr AC, Rosengrave P, Bayer S, Chambers S, Mehrtens J, Shaw GM (2017) Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes. Crit Care 21:300
doi: 10.1186/s13054-017-1891-y
Fowler AA, Truwit JD, Hite RD (2019) Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA 322:1261–1270. https://doi.org/10.1001/jama.2019.11825
doi: 10.1001/jama.2019.11825
pubmed: 31573637
pmcid: 6777268
Hoang BX, Show G, Fang W, Han B (2020) Possible application of high-dose vitamin C in the prevention and therapy of coronavirus infection. J Glob Antimicrob Resist 23:256–262. https://doi.org/10.1016/j.jgar.2020.09.025
doi: 10.1016/j.jgar.2020.09.025
pubmed: 33065330
pmcid: 7553131
Kashiouris MG, L’Heureux M, Cable CA, Fisher BJ, Leichtle SA, Fowler AA (2020) The emerging role of vitamin C as a treatment for sepsis. Nutrients 12(2):292. https://doi.org/10.3390/nu12020292
doi: 10.3390/nu12020292
pmcid: 7070236
Mark PE, Khangoora V, Rivera R, Hooper MH, Catravas J (2017) Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock. Chest 151(6):1229–1238. https://doi.org/10.1016/j.chest.2016.11.036
doi: 10.1016/j.chest.2016.11.036
Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04264533
Zhang J, Rao X, Li Y et al (2021) Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann Intensive Care 11:5. https://doi.org/10.1186/s13613-020-00792-3
doi: 10.1186/s13613-020-00792-3
pubmed: 33420963
pmcid: 7794643
Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Gallaghe, Muller WJ, O’Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y (2020) Guidelines on the treatment and management of patients with COVID-19. Inf Dis Soc Am. https://www.idsociety.org/COVID19guidelines
Wu JT, Leung K, Bushman M et al (2020) Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med 26:506–510. https://doi.org/10.1038/s41591-020-0822-7
doi: 10.1038/s41591-020-0822-7
pubmed: 32284616
pmcid: 7094929
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8 (PMID: 3558716)
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11(2):31. https://doi.org/10.1186/cc5713 (PMID: 17331245; PMCID: PMC2206446)
doi: 10.1186/cc5713
de Grooth HJ, Manubulu-Choo WP, Zandvliet AS, Spoelstra-de Man AME, Girbes AR et al (2018) Vitamin c pharmacokinetics in critically Ill patients: a randomized trial of four IV regimens. Chest 153(6):1368–1377
doi: 10.1016/j.chest.2018.02.025
Hemilä H, Chalker E (2020) Vitamin C may reduce the duration of mechanical ventilation in critically ill patients: a meta-regression analysis. J Intensive Care 7(8):15. https://doi.org/10.1186/s40560-020-0432-y (PMID: 32047636; PMCID: PMC7006137)
doi: 10.1186/s40560-020-0432-y
Holford P, Carr AC, Jovic TH, Ali SR, Whitaker IS, Marik PE, Smith AD (2020) Vitamin C—an adjunctive therapy for respiratory infection, sepsis and COVID-19. Nutrients 12(12):3760
doi: 10.3390/nu12123760
Fontana F et al (2020) oxalate nephropathy caused by excessive vitamin C administration in 2 patients with COVID-19. Kidney Int Rep 5(10):1815–1822
doi: 10.1016/j.ekir.2020.07.008
Keddissi JI, Youness HA, Jones KR, Kinasewitz GT (2018) Fluid management in acute respiratory distress syndrome: a narrative review. Can J Respir Ther 55:1–8. https://doi.org/10.29390/cjrt-2018-016
doi: 10.29390/cjrt-2018-016
pubmed: 31297439
pmcid: 6591787
Zhao B, Ling Y, Li J, Peng Y, Huang J, Wang Y, Qu H, Gao Y, Li Y, Hu B, Lu S, Lu H, Zhang W, Mao E (2020) Beneficial aspects of high dose intravenous vitamin C on patients with COVID-19 pneumonia in severe condition: a retrospective case series study. Ann Palliat Med. https://doi.org/10.21037/apm-20-1387 . Epub ahead of print. PMID: 33222462
Hiedra R, Lo KB, Elbashabsheh M et al (2020) The use of IV vitamin C for patients with COVID-19: a case series. Expert Rev Anti Infect Ther 18(12):1259–1261. https://doi.org/10.1080/14787210.2020.1794819
doi: 10.1080/14787210.2020.1794819
pubmed: 32662690
Carr AC, Rowe S (2020) The emerging role of vitamin C in the prevention and treatment of COVID-19. Nutrients 12(11):3286. https://doi.org/10.3390/nu12113286 (PMID: 33121019; PMCID: PMC7693980)
doi: 10.3390/nu12113286
pmcid: 7693980